Fig. 5

5-AZA disrupts the interaction between active RNA-pol-II complex and hnRNPK/RCMT complex. a Examination of the effects of various epigenetic drugs on the growth of OCI-M2 and SC leukaemia cells. b Examination of the interactions between hnRNPK and the components of active RNA-pol-II complex and their RNA-dependence by RNase digestion-coupled co-IPs in OCI-M2 cells. c Elucidation of the subcellular localization and co-localization of hnRNPK with active RNA-pol-II CTD-S2P at nascent RNA in OCI-M2 cells by 5-ethynyluridine (EU) clicking chemistry STED confocal microscopy in OCI-M2 and M2AR cells. d Examination of the effects of 5-AZA on the interactions between hnRNPK and the components of active RNA-pol-II complex, including RNA-pol-II CTD-S2P, RNA-pol-II S5P, CDK7 and CDK9/P-TEFb in OCI-M2 cells treated with 1 μM 5-AZA for various times. e Examination of the effects of 5-AZA on the interactions between hnRNPK and DNMT2 as well as NSUN3 by co-IPs in OCI-M2 cells treated with 1 μM 5-AZA for various times. f A schematic presentation of the hnRNPK/RCMT-associated, 5-AZA-sensitive, active chromatin structure at nascent RNA in 5-AZA-sensitive leukaemia cells